@pesquallie I would be hesitant to use conclusions extrapolated from trials treating patients with advanced “late-stage, therapy resistant prostate cancers using a monthly, high-dose injection of testosterone” to patients with much earlier stage lower-grade disease.

They state that, “For decades, the goal of endocrine therapy in prostate cancer has been to achieve absolute inhibition of androgen receptor function, the protein that senses testosterone levels…..It’s been a highly effective strategy, leading to substantial improvements in overall survival….Unfortunately, most patients with advanced, metastatic disease who are treated with drugs to inhibit androgen signaling will progress to an aggressive form of the disease for which there are limited therapeutic options.”

Basically, what they’re saying is for lower grade prostate cancer, use ADT as planned; for advanced metastatic disease, consideration of BAT (or some other protocol) might be more appropriate.